Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6.

Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6.

To provide a particle labeling reagent having low luminescent characteristics and improved water solubility.

Provided is a particle labeling reagent containing a compound represented by the following general formula (I-1) or (I-2).

##STR00001## (In the above general formula (I-1), p represents an integer of 1 to 3. In the above general formula (I-1), M represents a hydrogen atom or a mono- to tri-valent metal atom. In the above general formula (I-1), L.sup.1 represents a single bond or a (p+1)-valent group. In the above general formulas (I-1) and (I-2), L.sup.2 and L.sup.3 each independently represent a hydrogen atom or a photodegradable protecting group, and L.sup.2 and L.sup.3 may be the same or different. Provided that at least one of L.sup.2 and L.sup.3 represents a photodegradable protecting group. In the above general formula (I-2), L.sup.4 represents a monovalent group.)

Among the various aspects of the present disclosure is the provision of methods and compositions for detecting recombinant cationic ferritin imaging agents. Also provided are transgenic microorganisms capable of synthesizing a recombinant ferritin imaging agent and methods of making the same. The imaging agents described herein can be used to effectively and noninvasively detect renal pathologies and are suitable for use in a number of imaging modalities.

Among the various aspects of the present disclosure is the provision of methods and compositions for detecting recombinant cationic ferritin imaging agents. Also provided are transgenic microorganisms capable of synthesizing a recombinant ferritin imaging agent and methods of making the same. The imaging agents described herein can be used to effectively and noninvasively detect renal pathologies and are suitable for use in a number of imaging modalities.

Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.

Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.

A molecular probe comprising a linear peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; a contrast agent; and a non-peptide linker that covalently links the peptide to the contrast agent.

A molecular probe comprising a linear peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; a contrast agent; and a non-peptide linker that covalently links the peptide to the contrast agent.

The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (V.sub.L) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.